melatonin has been researched along with Cardiomyopathies in 18 studies
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin is a documented potent antioxidant, nontoxic and cardioprotective agent, and it is involved in maintaining mitochondrial homeostasis and function." | 5.48 | AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis. ( Di, S; Liu, D; Ma, Z; Qiao, S; Reiter, RJ; Xu, L; Yang, J; Yang, Y; Yuan, J, 2018) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| " Myocyte necrosis and fibrosis were diminished with melatonin while vasculitis was prevented." | 3.80 | Histopathological evaluation of melatonin as a protective agent in heart injury induced by radiation in a rat model. ( Erkal, HŞ; Gürses, I; Özeren, M; Serin, M; Yücel, N, 2014) |
| "Melatonin is a hormone secreted by the pineal gland under the control of the circadian rhythm, and is released in the dark and suppressed during the day." | 2.61 | A new prospective on the role of melatonin in diabetes and its complications. ( Chye, SM; Koh, RY; Mok, JX; Ng, KY; Ooi, JH, 2019) |
| "Melatonin is a kind of hormone well known for its antioxidant properties, which has potential protective effects against diabetes mellitus and its complications." | 1.62 | Melatonin Attenuates Diabetic Myocardial Microvascular Injury through Activating the AMPK/SIRT1 Signaling Pathway. ( Bao, M; Chen, M; Chen, R; Gao, F; Huang, D; Li, H; Li, J; Lu, B; Shi, G; Wang, B; Zhang, Y, 2021) |
| "Melatonin and irisin cotreatment effectively inhibited the Mst1-JNK pathway and, thus, promoted cardiomyocyte survival and mitochondrial homeostasis." | 1.56 | Combination of melatonin and irisin ameliorates lipopolysaccharide-induced cardiac dysfunction through suppressing the Mst1-JNK pathways. ( Deng, Y; Hu, Y; Li, Q; Lu, J; Ouyang, H; Xia, F; Zheng, S; Zhong, J, 2020) |
| "The melatonin treatment attenuated septic myocardial injury in a comparable manner to the genetic depletion of Ripk3." | 1.51 | Therapeutic contribution of melatonin to the treatment of septic cardiomyopathy: A novel mechanism linking Ripk3-modified mitochondrial performance and endoplasmic reticulum function. ( Chen, S; Chen, Y; Guo, Z; Hu, Y; Liu, J; Lu, J; Tan, Y; Xiao, X; Zheng, S; Zhong, J; Zhu, P, 2019) |
| "Melatonin is a documented potent antioxidant, nontoxic and cardioprotective agent, and it is involved in maintaining mitochondrial homeostasis and function." | 1.48 | AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis. ( Di, S; Liu, D; Ma, Z; Qiao, S; Reiter, RJ; Xu, L; Yang, J; Yang, Y; Yuan, J, 2018) |
| "Melatonin is a pineal hormone with free radical scavenging activity on oxidants; therefore it may decrease the ADM-induced oxidative stress and cardiotoxicity so that therapeutic efficacy might be enhanced." | 1.36 | Role of exogenous melatonin on adriamycin-induced changes in the rat heart. ( Aydemir, S; Kart, A; Ozdemir, I, 2010) |
| "Melatonin and probucol were equally effective in inhibiting the increase in myocardial TBARS as well as zinc levels, suggesting that myocardial zinc accumulation might be a protective response against adriamycin-induced oxidative stress." | 1.30 | Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant. ( Hayakawa, M; Hayakawa, T; Ito, T; Kaneko, S; Kawakami, K; Matsui, H; Mokuno, S; Morishima, I; Numaguchi, Y; Okumura, K; Toki, Y, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Wang, X | 1 |
| Tang, Y | 1 |
| Huang, C | 1 |
| Taha, AM | 1 |
| Mahmoud, AM | 1 |
| Ghonaim, MM | 1 |
| Kamran, A | 1 |
| AlSamhori, JF | 1 |
| AlBarakat, MM | 1 |
| Shrestha, AB | 1 |
| Jaiswal, V | 1 |
| Reiter, RJ | 3 |
| Zhang, J | 2 |
| Wang, L | 1 |
| Xie, W | 1 |
| Hu, S | 1 |
| Zhou, H | 1 |
| Zhu, P | 2 |
| Zhu, H | 1 |
| Mok, JX | 1 |
| Ooi, JH | 1 |
| Ng, KY | 1 |
| Koh, RY | 1 |
| Chye, SM | 1 |
| Ouyang, H | 1 |
| Li, Q | 1 |
| Zhong, J | 2 |
| Xia, F | 1 |
| Zheng, S | 2 |
| Lu, J | 2 |
| Deng, Y | 1 |
| Hu, Y | 2 |
| Jiang, J | 1 |
| Liang, S | 1 |
| Du, Z | 1 |
| Xu, Q | 1 |
| Duan, J | 1 |
| Sun, Z | 1 |
| Wang, B | 1 |
| Li, J | 1 |
| Bao, M | 1 |
| Chen, R | 1 |
| Li, H | 1 |
| Lu, B | 1 |
| Chen, M | 1 |
| Huang, D | 1 |
| Zhang, Y | 1 |
| Gao, F | 1 |
| Shi, G | 1 |
| Liu, D | 1 |
| Ma, Z | 1 |
| Di, S | 1 |
| Yang, Y | 1 |
| Yang, J | 1 |
| Xu, L | 1 |
| Qiao, S | 1 |
| Yuan, J | 1 |
| Tan, Y | 1 |
| Liu, J | 1 |
| Xiao, X | 1 |
| Chen, S | 1 |
| Chen, Y | 1 |
| Guo, Z | 1 |
| Dominguez-Rodriguez, A | 1 |
| Abreu-Gonzalez, P | 1 |
| Gürses, I | 1 |
| Özeren, M | 1 |
| Serin, M | 1 |
| Yücel, N | 1 |
| Erkal, HŞ | 1 |
| Veneroso, C | 1 |
| Tuñón, MJ | 1 |
| González-Gallego, J | 1 |
| Collado, PS | 1 |
| Aydemir, S | 2 |
| Ozdemir, I | 2 |
| Kart, A | 1 |
| Koçak, G | 1 |
| Erbil, KM | 1 |
| Sunar, B | 1 |
| Tuncel, M | 1 |
| Atalay, S | 1 |
| Natelson, BH | 1 |
| Ottenweller, JE | 1 |
| Tapp, WN | 1 |
| Heung, S | 1 |
| Beldowicz, D | 1 |
| Morishima, I | 1 |
| Okumura, K | 1 |
| Matsui, H | 1 |
| Kaneko, S | 1 |
| Numaguchi, Y | 1 |
| Kawakami, K | 1 |
| Mokuno, S | 1 |
| Hayakawa, M | 1 |
| Toki, Y | 1 |
| Ito, T | 1 |
| Hayakawa, T | 1 |
| Karpov, RS | 1 |
| Slepushkin, VD | 1 |
| Mordovin, VF | 1 |
| Zykova, VA | 1 |
| Khavinson, VKh | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Association Between Plasma Melatonin and No-reflow[NCT03306303] | 1,700 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for melatonin and Cardiomyopathies
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Melatonin as a potential treatment for septic cardiomyopathy.
Topics: Antioxidants; Cardiomyopathies; Cardiovascular Diseases; Humans; Melatonin; Sepsis | 2023 |
A new prospective on the role of melatonin in diabetes and its complications.
Topics: Animals; Antioxidants; Apoptosis; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus; Diabe | 2019 |
1 trial available for melatonin and Cardiomyopathies
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
15 other studies available for melatonin and Cardiomyopathies
| Article | Year |
|---|---|
Melatonin alleviates doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, pyroptosis and apoptosis by activating Sirt1/Nrf2 pathway.
Topics: Animals; Apoptosis; Cardiomyopathies; Cardiotoxicity; Doxorubicin; Heart Injuries; Melatonin; Mice; | 2023 |
Melatonin attenuates ER stress and mitochondrial damage in septic cardiomyopathy: A new mechanism involving BAP31 upregulation and MAPK-ERK pathway.
Topics: Animals; Cardiomyopathies; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Lipopolysaccharides; | 2020 |
Combination of melatonin and irisin ameliorates lipopolysaccharide-induced cardiac dysfunction through suppressing the Mst1-JNK pathways.
Topics: Animals; Apoptosis; Cardiomyopathies; Cells, Cultured; Fibronectins; Heart; Hepatocyte Growth Factor | 2020 |
Melatonin ameliorates PM
Topics: Acetylation; Animals; Antioxidants; Cardiomyopathies; Cardiotoxicity; Cell Line; Disease Models, Ani | 2021 |
Melatonin Attenuates Diabetic Myocardial Microvascular Injury through Activating the AMPK/SIRT1 Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Cardiomyopathies; Disease Models, Animal; Huma | 2021 |
AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis.
Topics: AMP-Activated Protein Kinases; Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiomyopathies; Ca | 2018 |
Therapeutic contribution of melatonin to the treatment of septic cardiomyopathy: A novel mechanism linking Ripk3-modified mitochondrial performance and endoplasmic reticulum function.
Topics: Cardiomyopathies; Cardiotonic Agents; Cytoskeleton; Endoplasmic Reticulum; Endoplasmic Reticulum Str | 2019 |
The potential usefulness of serum melatonin level to predict heart failure in patients with hypertensive cardiomyopathy.
Topics: Cardiomyopathies; Female; Heart Failure; Humans; Hypertension; Male; Melatonin; Middle Aged; Predict | 2014 |
Histopathological evaluation of melatonin as a protective agent in heart injury induced by radiation in a rat model.
Topics: Animals; Cardiomyopathies; Coronary Artery Disease; Coronary Vessels; Cytoprotection; Fibrosis; Male | 2014 |
Melatonin reduces cardiac inflammatory injury induced by acute exercise.
Topics: Animals; Cardiomyopathies; Cyclooxygenase 2; Disease Models, Animal; Inflammation; Intercellular Adh | 2009 |
Role of exogenous melatonin on adriamycin-induced changes in the rat heart.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Cardiomyopathies; Catalase; Doxorubicin; Lipid P | 2010 |
The protective effect of melatonin on adriamycin-induced acute cardiac injury.
Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; | 2003 |
The pineal affects life span in hamsters with heart disease.
Topics: Animals; Cardiomyopathies; Circadian Rhythm; Cricetinae; Heart Failure; Longevity; Male; Melatonin; | 1997 |
Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant.
Topics: Animals; Antioxidants; Ascites; Body Weight; Cardiomyopathies; Doxorubicin; Heart Ventricles; Lipid | 1999 |
[Pathogenesis and diagnosis of dysovarian cardiomyopathy].
Topics: Adult; Cardiomyopathies; Climacteric; Electrolytes; Estradiol; Female; Gonadotropins, Pituitary; Hum | 1986 |